References
- Biollaz J., Brunner H. R., Gavras I., Waeber B., Gavras H. Antihypertensive therapy with MK421: angiotensin II‐renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 1982; 4: 966
- Corea L., Bentivoglio M., Verdecchia P., Motolese M. Role of adrenergic overactivity and pressure overload in the pathogenesis of left ventricular hypertrophy in borderline and sustained essential hypertension in man. Clin. Sci. 1982; 63: 379s
- Culpepper W. S., III, Sodt P. C., Messerli F. H., Ruschhanpt D. G., Achilla R. A. Cardiac status in juvenile borderline hypertension. Ann. Intern. Med. 1983; 98: 1
- Idikio H., Fernandez P. G., Triggle C. R., Kim B. K. Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR): oxprenolol versus hydrochlorothiazide. Clin. Invest. Med. 1983; 6: 43
- Iwai J., Edward V., Dahl L. K. Influence of thiazide on salt hypertension. Circ. Res. 1977; 40(Suppl. I)131
- Rapp J. P. Dahl salt‐susceptible and salt resistant rats: A review. Hypertension 1982; 4: 753
- Richer C., Doussau M. P., Giudicelli J. F. MK421 and prevention of genetic hypertension development in young spontaneously hypertensive rats. Eur. J. Pharmacol. 1982; 19: 23
- Saragoca M. A., Tarazi R. C. Left ventricular hypertrophy in rats with renovascular hypertension. Hypertension 1981; 3(Suppl II)171
- Sen S., Tarazi R. C., Bumpus F. M. Biochemical changes associated with development and reversal of cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc. Res. 1976; 10: 254
- Sen S., Tarazi C. R., Bumpus F. M. Effect of converting enzyme inhibitor (SQ 14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980; 2: 169
- Sen S., Tarazi R. C., Khairallah P. A., Bumpus F. M. Cardiac hypertrophy in spontaneously hypertensive rats. Circ. Res. 1974; 35: 775
- Sharma J. N., Fernandez P. G., Kim B. K., Idikio H., Triggle C. R. Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide. J. Hypertension 1983; 1: 251
- Sweet C. S., Ulm E. H., Gross D. M., Vassil T. C., Stone C. A. A new class of angiotensin converting enzyme inhibitors. Nature 1980; 288: 280
- Tarazi R. C., Gifford R. W. Left ventricular hypertrophy and hypertension. Ann. Intern. Med. 1983; 250: 1319
- Tarazi R. C. Reversal of left ventricular by drug therapy. The Therapeutics of Hypertension, J. I.S. Robertson, G. W. Pickering, A. D.S. Caldwell. The Royal Society of Medicine and Academic Press, London 1980; 202
- Tarazi R. C., Saragoca M., Khairallah P. A. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur. Heart J. 1982; 3: 103
- Tarazi R. C. The role of the heart in hypertension. Clin. Sci. 1982; 63: 347s
- Tobian L., Lange J., Iwai J., Hiller K., Johnson M. N., Goosens P. Prevention with thiazide of NaCl‐induced hypertension in Dahl 'S' rats. Hypertension 1979; 1: 316
- Wilkins L. H., Dustan H. P., Walker J. F., Oparil S. Enalapril in low‐renin essential hypertension. Clin. Pharmacol. Ther. 1983; 34: 297
- Yin F. C.P. Ventricular wall stress. Circ. Res. 1981; 49: 829